
Product Data Sheet

Product Name: 4-iodo-SAHA

Cat. No.: GC17005

Chemical Properties

Cas. No. 1219807-87-0

Chemical Name N1-hydroxy-N8-(4-iodophenyl) octanediamide

SMILES IC1=CC=C(NC(CCCCCC(=O)N)=O)C=C1Formula $C_{14}H_{19}IN_2O_3$ M.Wt 390.2Solubility $\geq 1.67\text{mg/mL}$ in DMSO Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure **Background**

4-iodo-SAHA is a hydrophobic derivative of SAHA, the class I and class II histone deacetylase (HDAC) inhibitor [1].

The reversible acetylation of lysine residues in histone plays an important role in transcriptional activation and repression. The regulation of these post-translational modifications is balanced by histone acetyltransferase (HAT) and histone deacetylase (HDAC) activities. HDACs are also involved in reversible acetylation of non-histone proteins [1].

4-iodo-SAHA is a histone deacetylase (HDAC) inhibitor. In SKBR3-breast-derived cell line, 4-iodo-SAHA inhibited cell proliferation with EC50 value of $1.1\ \mu\text{M}$. In HT29 colon-derived cell line, leukemia-derived U937 tumor cell line, JA16, HL60 and K562 cell lines, 4-iodo-SAHA inhibited cell proliferation with EC50 values of 0.95 , 0.12 , 0.24 , 0.85 and $1.3\ \mu\text{M}$, respectively. 4-iodo-SAHA is 10-fold more potent as an inhibitor of U937 leukemia cell proliferation compared to SAHA ($0.12\ \mu\text{M}$ versus $1.2\ \mu\text{M}$). In SKBR3 cells, 4-iodo-SAHA

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

reduced acetylated H4 and p21 levels [1].

Reference:

[1]. Salmi-Smail C, Fabre A, Dequiedt F, et al. Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity. J Med Chem. 2010 Apr 22;53(8):3038-47.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA